These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 14423447)

  • 1. [Hazards of urological androgen therapy and the depot preparations].
    MOLNAR J
    Orv Hetil; 1959 Nov; 100():1585-7. PubMed ID: 14423447
    [No Abstract]   [Full Text] [Related]  

  • 2. New long-acting androgens.
    Gooren LJ
    World J Urol; 2003 Nov; 21(5):306-10. PubMed ID: 14551719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative characteristics of testosterone preparations for androgen-replacing therapy in male hypogonadism].
    Iudovskiĭ SO; Segal AS; Pushkar' DIu
    Urologiia; 2006; (3):83-4, 86-8. PubMed ID: 16889100
    [No Abstract]   [Full Text] [Related]  

  • 4. Metabolic balance studies of a patient with multiple myeloma given combined ACTH-androgen therapy: comparisons of three androgens administered in varying dosage on exchanges of calcium, phosphorus and nitrogen.
    SKOOG WA; ADAMS WS
    Metabolism; 1962 Jun; 11():614-25. PubMed ID: 13913685
    [No Abstract]   [Full Text] [Related]  

  • 5. Randomized cross-over clinical trial of injectable vs. implantable depot testosterone for maintenance of testosterone replacement therapy in androgen deficient men.
    Fennell C; Sartorius G; Ly LP; Turner L; Liu PY; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2010 Jul; 73(1):102-9. PubMed ID: 19891698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
    Behre HM; Nashan D; Hubert W; Nieschlag E
    J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of prostate cancer by androgens: experimental paradox or clinical reality.
    Algarté-Génin M; Cussenot O; Costa P
    Eur Urol; 2004 Sep; 46(3):285-94; discussion 294-5. PubMed ID: 15306098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Absence of water-salt retention following the injection of a delayed-action estrogen-progesterone-androgen combination].
    LINQUETTE M; FOSSATI P
    Lille Med; 1962; 7():557-60. PubMed ID: 14465640
    [No Abstract]   [Full Text] [Related]  

  • 10. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men.
    Dinsmore WW; Wyllie MG
    BJU Int; 2012 Jul; 110(2):162-9. PubMed ID: 22288877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy.
    Beer TM; Garzotto M; Eilers KM; Lemmon D
    J Urol; 2003 May; 169(5):1738-41. PubMed ID: 12686821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen replacement in menopause.
    Burd ID; Bachmann GA
    Curr Womens Health Rep; 2001 Dec; 1(3):202-5. PubMed ID: 12112971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin A and iron supplementation is as efficient as hormonal therapy in constitutionally delayed children.
    Zadik Z; Sinai T; Zung A; Reifen R
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):682-7. PubMed ID: 15163330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of estrogen/androgen regimens.
    Simon JA
    J Reprod Med; 2001 Mar; 46(3 Suppl):281-90. PubMed ID: 11304876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery of testosterone replacement therapy.
    Hameed A; Brothwood T; Bouloux P
    Curr Opin Investig Drugs; 2003 Oct; 4(10):1213-9. PubMed ID: 14649214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer risk in testosterone-treated men.
    Raynaud JP
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):261-6. PubMed ID: 17113983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should women receive androgen replacement therapy, and if so, how?
    Davis SR
    Clin Endocrinol (Oxf); 2010 Feb; 72(2):149-54. PubMed ID: 19650781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen replacement in women: a commentary.
    Davis S
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1886-91. PubMed ID: 10372681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen deficiency in the aging male: a guide to diagnosis and testosterone replacement therapy.
    Raynor MC; Carson CC; Pearson MD; Nix JW
    Can J Urol; 2007 Dec; 14 Suppl 1():63-8. PubMed ID: 18163948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone release rate and duration of action of testosterone pellet implants.
    Kelleher S; Howe C; Conway AJ; Handelsman DJ
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):420-8. PubMed ID: 15049955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.